Attorney Erin Copeland, partner of Fibich, Leebron, Copeland, Briggs &
Josephson has recently been appointed to the Essure Executive Committee
for California as a Judicial Council Coordinate Proceeding (JCCP). Erin
has been a prominent leader in the fight against Essure and often speaks
out about the dangers of this risky medical device. Essure is a birth
control device made out of nickel and titanium, which is implanted into
a woman’s fallopian tubes to block sperm, thereby preventing pregnancy.
The FDA reported that over 9,000 women submitted voluntary complaints against
Essure. Many of the complications reported about the device include ectopic
pregnancy, fetal death, additional surgeries, and hysterectomies to remove
Essure and repair organs. Despite Bayer’s denial of any wrongdoing,
the device was given a black box warning by the FDA, indicating that the
product may cause serious injuries or death. It is the FDA’s highest
Attorney Erin Copeland is one of five attorneys appointed to the Essure
Executive Committee to lead the pretrial proceedings on behalf of all
plaintiffs in the California coordinated litigation Essure Product Cases.
The Executive Committee is comprised of: Fidelma Fitzpatrick of Motley
Rice; Kim Dougherty; M. Elizabeth Graham of Grant & Eisenhofer P.A.;
Edward A. Wallace of Wexler Wallace LLP. Fidelma Fitzpatrick will chair
the Executive Committee. M. Elizabeth Graham and William A. Kershaw of
Kershaw, Cook & Talley will act as co-liaisons.
Read the full press release